James Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,095 shares of the company’s stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $18,669.75. Following the transaction, the insider now owns 21,275 shares in the company, valued at $362,738.75. This represents a 4.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

James Kihara also recently made the following trade(s):

• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD stock opened at $17.19 on Friday. The stock has a fifty day simple moving average of $18.35 and a two-hundred day simple moving average of $17.02. The firm has a market capitalization of $2.87 billion, a PE ratio of 22.04 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $20.68.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Morgan Stanley restated an “equal weight” rating and set a $20.00 price target on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.93.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors have recently made changes to their positions in ACAD. Point72 Asset Management L.P. purchased a new position in ACADIA Pharmaceuticals in the 4th quarter worth approximately $40,935,000. SG Americas Securities LLC raised its position in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after buying an additional 1,966,607 shares during the last quarter. Norges Bank purchased a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth $25,555,000. Renaissance Technologies LLC grew its stake in ACADIA Pharmaceuticals by 204.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company’s stock valued at $22,507,000 after acquiring an additional 823,333 shares in the last quarter. Finally, Two Sigma Advisers LP grew its stake in ACADIA Pharmaceuticals by 160.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company’s stock valued at $23,180,000 after acquiring an additional 778,900 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.